This content is from:xinyabo体育
ValueAct’s Valeant Problem
Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?
Photo credit: BloombergBy Michelle Celarier ValueAct Capital Management’s Jeffrey Ubben has carefully cultivated a reputation as a good-guy activist who works with management to get results — a reputation that was built in part on his tremendous success with Canadian drugmaker Valeant Pharmaceuticals International. Valeant soared for years, helping fuel such
To continue reading,subscribe nowto Premium Journalism. Already a subscriber?Login.